Elif Sibel ASLAN, Sefa ÇETİNKAYA

Use of miRNA as a Biomarker in Prostate Cancer and New Approaches

Prostate cancer has been found to be the most life-threatening disease among men all over the world,given its wide occurrence and partially-successful therapies associated with a high rate of mortality.Thus, meticulous analysis of this cancer and its characteristics, including molecular biology, epigeneticmechanisms and markers during tumor development, may provide the scientists with valuable insightsto design the therapeutic protocol with improved efficiency and low rate of failure and limited furtherside effects, such as infertility. Moreover, the risk associated with the current invasive procedures onprostate cancer patients has prompted researchers to invest effort in the discovery of being less-invasiveand more advantageous procedures based on the patient’s own physiological and anatomical characteristics. This paper reviews past and present studies on epigenetics and molecular markers of prostatecancer, as well as the designed therapies. Additionally, we present a future vision and prospect of thecurrent treatments.

PDF

___

1. Maitland NJ. Stem Cells in the Normal and Malignant Prostate. In: Tindall DJ, editor. Prostate Cancer–Biochemistry, Molecular Biology and Genetics. New York: Springer; 2013. p. 3−41.
2. Capasso LL. Antiquity of cancer. Int J Cancer 2005;113(1):2−13.
3. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8(4):268−78.
4. Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4(11):876−90.
5. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007;53(8):1423−32.
6. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17(2):159−63.
7. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80(2):281−5.
8. Gupta N, Sudhakar DVS, Gangwar PK, Sankhwar SN, Gupta NJ, Chakraborty B, et al. Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility. Sci Rep 2017;7(1):11225.
9. Emami N, Deperthes D, Malm J, Diamandis EP. Major role of human KLK14 in seminal clot liquefaction. J Biol Chem 2008;283(28):19561−9.
10.Frame FM, Maitland NJ Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv Exp Med Biol 2011;720:105−18.
11.Greenberg R. Does prostate cancer represent more than one cancer? In: Prostate Cancer: Science and Clinical Practice. Mydlo JH, Godec CJ, editors. 1st edition. San Diego: Academic Press; 2003. p. 29−34.
12.Robinson EJ, Neal DE, Collins AT. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998;37(3):149−60.
13.Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33−50.
14.Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117(Pt 16):3539−45.
15.Demichelis F, Stanford JL. Genetic predisposition to prostate cancer: Update and future perspectives. Urol Oncol 2015;33(2):75−84.
16.Swierczynski S, Klieser E, Illig R, Alinger-Scharinger B, Kiesslich T, Neureiter D. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther 2015;15(5):651−64.
17.Bacalini MG, Friso S, Olivieri F, Pirazzini C, Giuliani C, Capri M, et al. Present and future of anti-ageing epigenetic diets. Mech Ageing Dev 2014;136-137:101−15.
18.Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 2011;12(7):647−56.
19.Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38(12):1378−85.
20.Singh PK, Campbell MJ. The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. Cancers (Basel) 2013;5(3):998−1019.
21.Bishop KS, Ferguson LR. The interaction between epigenetics, nutrition and the development of cancer. Nutrients 2015;7(2):922−47.
22.Holliday R. Epigenetics: a historical overview. Epigenetics 2006;1(2):76−80.
23.Theodore SC, Davis M, Zhao F, Wang H, Chen D, Rhim J, et al. MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget 2014;5(11):3512−25.
24.Wang YL, Wu S, Jiang B, Yin FF, Zheng SS, Hou SC. Role of MicroRNAs in prostate cancer pathogenesis. Clin Genitourin Cancer 2015;13(4):260−70.
25. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14(14):R546−51.
26.Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002;108(4):475−87.
27.Fenrick R, Hiebert SW. Role of histone deacetylases in acute leukemia. J Cell Biochem Suppl 1998;30- 31:194−202.
28.Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther 2014;10(3):469−78.
29.Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009;28(14):1714−24.
30.Eeles RA, Al Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45(4):385−91, 391e1−2.
31.Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2013;22(2):408−15.
32.Fitzgerald LM, Kwon EM, Conomos MP, Kolb S, Holt S, Levine D, et al. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(6):1196−203.
33.Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;1487(7406):239−43.
34.Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87(6):417−26.
35.Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9(4):401−6.
36.Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 2016;375(5):443−53.
37.Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017;541(7637):359−64.
38.Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015;373(18):1697−708.
39.Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215−28.
40.Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44(6):685−9.
41.Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 2013;73(9):2795−805.
42.Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, et al. Synthetic essentiality of chromatin re-modelling factor CHD1 in PTEN-deficient cancer. Nature 2017;542(7642):484−8.
43.Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature 2017;546(7660):671−5.
44.Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, et al. Exome sequencing of AfricanAmerican prostate cancer reveals loss-of-function ERF mutations. Cancer Discov 2017;7(9):973−83.
45.Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644−8.
46.Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer 2017;17(6):337−51.
47.Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012;338(6113):1465−9.
48.Zhang C, Wang L, Wu D, Chen H, Chen Z, ThomasAhner JM, et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res 2011;71(21):6738−48.
49.Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163(4):1011−25.
50.Malik R, Khan AP, Asangani IA, Cieślik M, Prensner JR, Wang X, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med 2015;21(4):344−52.
51.Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castrationresistant neuroendocrine prostate cancer. Nat Med 2016;22(3):298−305.
52.Sehrawat A, Gao L, Wang Y, Bankhead A 3rd, McWeeney SK, King CJ, et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 2018;115(18):E4179−88.
53.Fan L, Zhang F, Xu S, Cui X, Hussain A, Fazli L, et al. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proc Natl Acad Sci U S A 2018;115(20):E4584−93.
54.Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1(6):487−95.
55.Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell 2016;30(4):563−77.
56.Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Protate Epithelial Cells. Cancer Cell 2016;29(4):536−47.
57.Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005;280(8):6511−9.
58.Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18(1):11−22.
59.He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43(1):69−77.
60.Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13(8):966−77.
61.Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4(3):209−21.
62.Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 2017;355(6320):78−83.
63.Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470(7333):269−73.
64.Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov 2016;6(1):80−95.
65.Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 2014;346(6205):85−89.
66.Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, et al. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 2017;31(3):436−51.
67.Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 2017;355(6320):84−8.
68.Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002;89(3):230−40.
69.Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol 2002;168(4 Pt 1):1412−4.
70.Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419(6907):624−9.
71.Taneja SS, Ha S, Garabedian MJ. Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression. J Cell Biochem 2001;84(1):188−99.
72.Bálint E E, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001;85(12):1813−23.
73.Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 2012;11(24):4579−88.
74.Taplin ME. Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 2008;8(9):1495−508.
75.Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002;99(6):3740−5.
76.Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, et al. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 2010;70(11):1166−78.
77.Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 2012;31(17):2153−63.
78.Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010;1803(11):1231−43.
79.Yang Y, Guo JX, Shao ZQ. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. Asian Pac J Trop Med 2017;10(1):87−91.
80.Sheng WZ, Chen YS, Tu CT, He J, Zhang B, Gao WD. MicroRNA-21 promotes phosphatase gene and protein kinase B/phosphatidylinositol 3-kinase expression in colorectal cancer. World J Gastroenterol 2016;22(24):5532−9.
81.Fragni M, Bonini SA, Bettinsoli P, Bodei S, Generali D, Bottini A, et al. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol 2016;389(5):529−38.
82.Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci A, Francescangeli F, et al. A microRNA code for prostate cancer metastasis. Oncogene 2016;35(9):1180−92.
83.Chen WX, Hu Q, Qiu MT, Zhong SL, Xu JJ, Tang JH, et al. miR-221/222: promising biomarkers for breast cancer. Tumour Biol 2013;34(3):1361−70.
84.Hao J, Zhang C, Zhang A, Wang K, Jia Z, Wang G, et al. miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncol Rep 2012;27(5):1504−10.
85.Jikuzono T, Kawamoto M, Yoshitake H, Kikuchi K, Akasu H, Ishikawa H, et al. The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol 2013;42(6):1858−68.
86.Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009;69(8):3356−63.
87.Yang X, Yang Y, Gan R, Zhao L, Li W, Zhou H, et al. Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS One 2014;9(6):e98833.
88.Matin F, Jeet V, Moya L, Selth LA, Chambers S; Australian Prostate Cancer BioResource, et al. A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer. Sci Rep 2018;8(1):6653.
89.Bond DR, Naudin C, Carroll AP, Goldie BJ, Brzozowski JS, Jankowski HM, et al. miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion. Oncotarget 2017;9(2):1980−91.
90.Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, et al. Expression of multidrug re-sistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 2004;93(1):98−106.
91.He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447(7148):1130−4.
92.Casanova-Salas I, Rubio-Briones J, Fernández-Serra A, López-Guerrero JA. miRNAs as biomarkers in prostate cancer. Clin Transl Oncol 2012;14(11):803−11.
93.Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, et al. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 2011;25(12):1849−56.
94.Feng B, Wang R, Chen LB. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother 2012;66(6):397−402.
95.Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008;27(31):4373−9.
96.Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67(13):6130−5.
97.Dahiya R, McCarville J, Lee C, Hu W, Kaur G, Carroll P, et al. Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int J Cancer 1997;72(2):283−8.
98.Ellsworth RE, Vertrees A, Love B, Hooke JA, Ellsworth DL, Shriver CD. Chromosomal alterations associated with the transition from in situ to invasive breast cancer. Ann Surg Oncol 2008;15(9):2519−25.
99.Rasio D, Negrini M, Manenti G, Dragani TA, Croce CM. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res 1995;55(18):3988−91.
100.Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y, et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010;116(24):5637−49.
101.Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104(40):15805−10.
102.Chen Y, Zaman MS, Deng G, Majid S, Saini S, Liu J, et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila) 2011;4(1):76−86.
103.Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, et al. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res 2012;72(14):3618−30.
104.Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128(3):608−16.
105.Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011;77(5):1265.e9−16.
106.Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Xou JX, et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS ONE 2012;7(3):e32832.
107.Beck J, Urnovitz HB, Riggert J, Clerici M, Schütz E. Profile of the circulating DNA in apparently healthy individuals. Clin Chem 2009;55(4):730−8.
108.Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 2015;61(1):239−48.
109.Liu QY, Rubin MA, Omene C, Lederman S, Stein CA. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res 1998;4(7):1803−11.
110.Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000;2(4):348−58.
111.Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357−65.
112.Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, et al. Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18(3):643−50.
113.Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2005;12(3):217−27.
114.Li J, Wang Y, Zhu Y, Oupický D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release 2013;172(2):589−600.
115.Nastiuk KL, Krolewski JJ. Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev 2016;98:35−40.
116.Ding H, Sun Y, Hou Y, Li L. Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3. Urol Oncol 2014;32(5):720−6.
117.Marangoni K, Neves AF, Rocha RM, Faria PR, Alves PT, Souza AG, et al. Prostate-specific RNA aptamer: promising nucleic acid antibody-like cancer detection. Sci Rep 2015;5:12090.
118.Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 2009;125(12):2978−90.
119.Kaikkonen MU, Ylä-Herttuala S, Airenne KJ. How to avoid complement attack in baculovirus-mediated gene delivery. J Invertebr Pathol 2011;107 Suppl:S71−9.
120.Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, et al. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol 2014;32(2):92−100.
121.Arafat W, Zhou T, Naoum GE, Buchsbaum DJ. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. J Egypt Natl Canc Inst 2015;27(4):205−15.
122.Ergün S. In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer. Dicle Med J 2018;45(4):415−29.
123.Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J, Burge CB. Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA 2007;13(11):1894−910.
124.Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120(1):15−20.
125.Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4(9):721−6.
126.Deiters A. Small molecule modifiers of the microRNA and RNA interference pathway. AAPS J 2010;12(1):51−60.
127.Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009;10(12):1252−9.
128.Poliseno L, Marranci A, Pandolfi PP. Pseudogenes in Human Cancer. Front Med 2015;2:68.
129.Karreth FA, Reschke M, Ruocco A, Ng C, Chapuy B, Léopold V, et al. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell 2015;161(2):319−32.
130.Kawamura N, Nimura K, Nagano H, Yamaguchi S, Nonomura N, Kaneda Y. CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells. Oncotarget 2015;6(26):22361−74.
131.Chen Z, Penet MF, Krishnamachary B, Banerjee SR, Pomper MG, Bhujwalla ZM. PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials 2016;80:57−67.
132.Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BRDIM. PLoS One 2012;7(3):e33729.
133.Chudley L, McCann K, Mander A, Tjelle T, CamposPerez J, Godeseth R, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high- -frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012;61(11):2161−70.
134.Fitzgerald KA, Guo J, Tierney EG, Curtin CM, Malhotra M, Darcy R, et al. The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics. Biomaterials 2015;66:53−66.
135.Souza AG, Marangoni K, Fujimura PT, Alves PT, Silva MJ, Bastos VA, et al. 3D Cell-SELEX: Development of RNA aptamers as molecular probes for PC-3 tumor cell line. Exp Cell Res 2016;341(2):147−56.
136.Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003;3(4):344−51.
137.Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9(4):809−24.
138.Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 2006;5(9):2203−10.
139.Taddei A, Roche D, Bickmore WA, Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 2005;6(6):520−4.
140.Bernhard D, Ausserlechner MJ, Tonko M, Löffler M, Hartmann BL, Csordas A, et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J 1999;13(14):1991−2001.
141.Ali SR, Humphreys KJ, McKinnon RA, Michael MZ. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. Drug Dev Res 2015;76(6):296−317.
142.Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med 2015;7(6):831−47.
143.Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010;127(6):1363−72.
144.Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010;103(2):256−64.
145.Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie 2015;117:119−28.
146.Jansen R, van Embden JD, Gaastra W, Schouls LM. Identification of a novel family of sequence repeats among prokaryotes. OMICS 2002;6(1):23−33.
147.Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007;315(5819):1709−12.
148.Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 2005;151(Pt 8):2551−61.
149.Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339(6121):819−23.
150.Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013;339(6121):823−6.
151.Yin Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, et al. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Mol Cancer 2019;18(1):11.
152.Guo X, Dean A. CRISPR/Cas9 offers a new tool for studying the role of chromatin architecture in disease pathogenesis. Genome Biol 2018; 6;19(1):185.
153.Takao A, Yoshikawa K, Karnan S, Ota A, Uemura H, De Velasco MA, Kura, et al. Generation of PTEN knockout ( / ) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling. Oncol Rep 2018;40(5):2455−66.
154.Albayrak G, Konac E, Ugras Dikmen A, Bilen CY. FOXA1 knock-out via CRISPR/Cas9 altered Casp9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells. Exp Biol Med (Maywood) 2018;243(12):990−4.
155.Takeda DY, Spisák S, Seo JH, Bell C, O’Connor E, Korthauer K, et al. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell 2018;174(2):422−32. e13.
156.Yu G, Cheng CJ, Lin SC, Lee YC, Frigo DE, Yu-Lee LY, et al. Organelle-Derived Acetyl-CoA Promotes Prostate Cancer Cell Survival, Migration, and Metastasis via Activation of Calmodulin Kinase II. Cancer Res 2018;78(10):2490−502.
157.Sorrentino C, Ciummo SL, Cipollone G, Caputo S, Bellone M, Di Carlo E, et al. Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization. Cancer Res 2018;78(10):2654−68.
158.Xu Y, Xu M, Zhang M, Tan J, Su Z, Chen X, et al. Knocking-out of HIF1α gene by CRISPR/cas9 inhibits proliferation and invasiveness of prostate cancer DU145 cells. [Article in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2018;35(2):160−4.
159.Wei C, Wang F, Liu W, Zhao W, Yang Y, Li K, et al. CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. Mol Med Rep 2018;17(2):2901−6.
160.Lopez-Guerrero AM, Pascual-Caro C, MartinRomero FJ, Pozo-Guisado E. Store-operated calcium entry is dispensable for the activation of ERK1/2 pathway in prostate cancer cells. Cell Signal 2017;40:44−52.
161.Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, et al. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci 2017;114(26):5207−15.
162.Protecting PTEN in the Nucleus. Cancer Discov 2017;7(4):OF1.
163.Zhen S, Takahashi Y, Narita S, Yang YC, Li X. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. Oncotarget 2017;8(6):9375−87.
164.Banerjee S, Li G, Li Y, Gaughan C, Baskar D, Parker Y, et al. RNase L is a negative regulator of cell migration. Oncotarget 2015;6(42):44360−72.